HOME >> BIOLOGY >> NEWS
Honey as healer

Ancient healer effective in treating infected skin lesions

Jem Bonnievale was 15 when he contracted meningococcal septicemia caused by an infection of Neisseria meningitidis. By the time the British teenager reached the hospital, he had multiple purple batches on his legs and fingers, which rapidly progressed to tissue death. Both legs were amputated below the knee as well as fingers on both hands. He endured multiple skin grafts and suffered for months with non-healing infected sores. His case was extreme and difficult to treat because of the severe pain it caused. "I can't even begin to explain how painful it was just to have a small piece of dressing changed. The nurses tried everything to make it easier, like changing the dressing in the bath, but it was agony," said Jem. Over the next six months the success of the grafts was variable and the sores showed heavy growth of Pseudomonas and Staphlococcus aureus. All traditional treatments were tried without success.

When nothing else had any effect on the chronic infected sores, clinical nurse Cheryl Dunford and her colleagues turned to honey. Dressing pads impregnated with sterilized active manuka honey from New Zealand were applied to one leg and a traditional dressing to the other leg. Within a few days, the honey dressed leg showed a reduction of wound bacteria. Both legs were then treated with the honey dressings. Within 10 weeks, all lesions were healed. Jem was released from the hospital, fitted with artificial legs and is getting on with his life.

The use of honey as medicine is mentioned in the most ancient written records. Today scientists and doctors are rediscovering the effectiveness of honey as a wound treatment. Dr. Peter Molan, Professor of Biochemisty at Waikato University, New Zealand has been on the forefront of honey research for 20 years. He heads the university's Honey Research Unit, which is internationally recognized for its expertise in the a
'"/>

Contact: Mary Ann Johnson
mjohnson@zfpartners.com
415-268-5421
Zuckerman Fernandes & Partners
31-Jul-2000


Page: 1 2

Related biology news :

1. Honey bee genome assembled
2. Honeybee gene find ends 150-year search
3. Honey bee genome being sequenced
4. Honey the darker the better Has potential as dietary antioxidant
5. USDA establishes Honeybee Genetics and IPM Center
6. Honey shines in athletic research, has scientific community abuzz
7. Honey : Naturess sweetener may increase recuperation after workouts
8. Honey may be the ideal pre-workout energy source
9. Honey in the medicine cabinet!
10. Dark Honey Has More Illness-Fighting Agents Than Light Honey
11. Summer Science: Where Have All The Honeybees Gone? UD Bee Guy Asks Why--From America To The Amazon

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Honey healer

(Date:7/7/2015)... 2015  Based on its recent analysis of ... Credence ID, LLC with the 2015 Asia-Pacific ... Year Award. Credence ID has developed a low-cost, ... of offering enrollment and identification solutions to the ... was formed by experts from the mobile biometrics ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
(Date:7/2/2015)... GOTHENBURG, Sweden , July 2, 2015 ... fingerprint sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor ... is one of FPC,s distributors in Asia ... Q4 2015. The sensors will be used by smartphone manufacturers ... 268 MSEK is included in the communicated revenue guidance of ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
(Date:7/30/2015)... ... , ... Ralco is honored to announce that it is the primary sponsor ... August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the ... their daily lives. This unique exhibit also features a birthing center for fair goers ...
(Date:7/30/2015)... July 30, 2015 According to ... (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, ... Preclinical, Clinical Trial), by End Users - Global Forecast ... expected to reach USD 2,107.99 million by 2020 from ... 15.29%. Browse more than ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
Cached News: